Hensoldts, Billion

Hensoldt's €110 Billion Pipeline Meets Its First Real Margin Test

Published on 11/12/2026 at 06:41 | Editorial boerse-global.de
Stifel and JPMorgan both see Hensoldt at €105, citing its product portfolio and capacity expansion as the company targets €6bn revenue by 2030.
Hensoldts, Billion, Pipeline, Meets, Its, First, Real, Test, Stifel, JPMorgan Illustration mit AI erstellt.

Two of the Street's most closely watched defence analysts have converged on the same price target for Hensoldt — and both now see the German sensor and electronic-warfare specialist as a stock to own. Stifel lifted its objective from €90 to €105 on Tuesday while reiterating its "Buy" rating, and JPMorgan matched that €105 figure, up from €100, alongside an upgrade from "Neutral" to "Overweight." The shares, for their part, slipped 1.6% on the day.

What unites the two calls is less the number than the reasoning: an attractive product portfolio and an expansion of manufacturing capacity that should allow Hensoldt to convert a swelling order book into revenue. That thesis now has a hard timetable attached to it, because the company's preliminary full-year 2026 figures are due on 24 February 2027 — the first proper audit of whether the growth story holds up in the accounts.

Ambition Gets a Longer Runway

At its capital markets day on Tuesday, Hensoldt reaffirmed its €6 billion revenue ambition for 2030 and, for the first time, set a longer-range target of €10 billion by 2035. Management also guided to annual top-line growth of 15–20% in both 2027 and 2028, with the adjusted EBITDA margin climbing to roughly 21% by 2030.

Those numbers sit atop a forecast firmed up only about a week earlier. After reporting nine-month results, Hensoldt specified 2026 revenue of around €2.8 billion and an adjusted EBITDA margin of about 19.0%. The nine-month figures themselves showed revenue of €1.86 billion against adjusted EBITDA of €281 million, while order intake reached €3.56 billion and the order backlog stood at €10.4 billion — new business running comfortably ahead of sales, which is the foundation on which the whole plan rests.

Should investors sell immediately? Or is it worth buying Hensoldt?

Beyond the backlog lies a larger pool of opportunity: an unweighted pipeline of roughly €110 billion covering 2027 to 2032. That figure signals the scale of what is potentially addressable, though its value to shareholders grows only as it converts into signed contracts.

Execution Is the Only Yardstick That Matters

The logic for investors is straightforward, and it runs in a fixed sequence: order intake first, then its translation into revenue, then the earnings power that follows. On the first count Hensoldt is well positioned — demand is not the constraint. The open question is throughput, and whether production capacity and programme execution can sustain a 15–20% annual pace.

That makes each upcoming set of results a stricter test than the last. The more ambitious the growth path, the less tolerance there is for slippage between bookings, sales and profitability. A margin that lands near the promised 19.0% for 2026, alongside revenue tracking toward €2.8 billion, would give the 2030 and 2035 targets genuine operational credibility.

For now the balance of the case favours the upside. Hensoldt has the order book to support expansion, two major houses have raised their sights to €105, and the long-term targets extend a decade out. What remains unresolved is the one thing no target can settle in advance: whether the business delivers. The 24 February print is where that judgment begins.

Ad

Hensoldt Stock: New Analysis - 12 November

Fresh Hensoldt information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Hensoldt analysis...

Disclaimer...
en | DE000HAG0005 | HENSOLDTS | boerse | 70495274 |